MainStreet Investment Advisors LLC Has $465,000 Stock Holdings in Charles River Laboratories International, Inc. $CRL

MainStreet Investment Advisors LLC increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 24.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,065 shares of the medical research company’s stock after purchasing an additional 600 shares during the quarter. MainStreet Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $465,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Teachers Retirement System of The State of Kentucky lifted its position in shares of Charles River Laboratories International by 2.7% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company’s stock valued at $589,000 after buying an additional 102 shares during the last quarter. GW&K Investment Management LLC increased its holdings in shares of Charles River Laboratories International by 41.1% during the 1st quarter. GW&K Investment Management LLC now owns 88,410 shares of the medical research company’s stock worth $13,307,000 after acquiring an additional 25,744 shares during the last quarter. Choreo LLC bought a new stake in Charles River Laboratories International in the 1st quarter valued at $283,000. Y Intercept Hong Kong Ltd acquired a new stake in Charles River Laboratories International during the 1st quarter valued at $566,000. Finally, Royce & Associates LP acquired a new stake in Charles River Laboratories International during the 1st quarter valued at $623,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on CRL shares. Mizuho upped their price objective on shares of Charles River Laboratories International from $155.00 to $174.00 and gave the company a “neutral” rating in a report on Friday, October 17th. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Morgan Stanley increased their price target on shares of Charles River Laboratories International from $170.00 to $185.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. TD Cowen cut their price objective on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Finally, JPMorgan Chase & Co. upped their target price on Charles River Laboratories International from $160.00 to $165.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $190.86.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $162.83 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $8.01 billion, a price-to-earnings ratio of -122.43, a price-to-earnings-growth ratio of 4.83 and a beta of 1.53. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $203.01. The company has a 50-day simple moving average of $168.87 and a two-hundred day simple moving average of $158.21.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. During the same quarter in the prior year, the business posted $2.59 EPS. The business’s revenue was down .5% compared to the same quarter last year. Analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).